Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00024531
Status:
COMPLETED
Last Update Posted:
2006-11-09
First Post:
2001-09-19
Brief Title:
Lipitor as a Treatment for Alzheimers Disease
Sponsor:
Institute for the Study of Aging ISOA
Organization:
National Institute on Aging NIA
Study Overview
Official Title:
Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium Lipitor in the Treatment of Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the clinical benefit of Lipitor a cholesterol-lowering drug in the treatment of Alzheimers disease
Detailed Description:
This study is a phase II placebo controlled double-blind one year trial investigating the effect of HmG-CoA reductase inhibitor atorvastatin calcium in the treatment of persons with possible or probable Alzheimers disease Subjects may continue to take stable doses of Aricept and Exelon Following enrollment participants will make visits to the study center every three months for blood tests and neuropsychological testing
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: